Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -5.80
- Piotroski Score 5.00
- Grade Overweight
- Symbol (CTMX)
- Company CytomX Therapeutics, Inc.
- Price $0.87
- Changes Percentage (-2.87%)
- Change -$0.03
- Day Low $0.85
- Day High $0.92
- Year High $5.85
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $5.84
- High Stock Price Target $8.00
- Low Stock Price Target $3.25
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.21
- Trailing P/E Ratio 7.81
- Forward P/E Ratio 7.81
- P/E Growth 7.81
- Net Income $-569,000
Income Statement
Quarterly
Annual
Latest News of CTMX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...
The CEO, Sean McCarthy, provided updates on CX-904 and CX-2051 programs, emphasizing dose escalation for CX-904 and progress into cohort five for CX-2051. Phase 1B decisions and updates are expected n...
By Yahoo! Finance | 1 week ago -
CytomX Therapeutics, Inc. (CTMX): The Best One-Dollar Stock to Buy Now?
The article discusses the current stock market trends and focuses on CytomX Therapeutics, a biotech company listed under one-dollar stocks. Despite promising technologies, risks like financial runway ...
By Yahoo! Finance | 3 months ago -
CytomX Therapeutics, Inc. (NASDAQ:CTMX) is definitely on the radar of institutional investors who own 47% of the company
Analyzing ownership data of a company like CytomX Therapeutics, Inc. can provide insights into future performance. Institutional investors hold a significant stake, influencing market decisions. Hedge...
By Yahoo! Finance | 3 months ago
